temozolomide,camrelizumab,rivoceranib
jiangsu hengrui pharmaceuticals,hlb bio group
['temozolomide', 'melanoma', 'camrelizumab', 'apatinib']
#camrelizumab plus #apatinib and #temozolomide as first-line treatment in patients with advanced acral #melanoma: the cap 03 phase 2 nonrandomized clinical trial #asco23 #meded #medtwitter #clinicaltrials 
Biomedical Science that Inspires. #medicine #medtwitter #meded #Science #Research #Technology #News